Comparative intravitreal antibiotic therapy for experimental Enterococcus faecalis endophthalmitis

Sangkyung Choi, Tae Won Hahn, Gerard Osterhout, Terrence O'Brien

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To evaluate the most effective intravitreal antibiotic treatment of vancomycin-sensitive and -resistant Enterococcus faecalis endophthalmitis. Design: Animal experiment. Setting: Seventy-eight New Zealand white rabbits received an intravitreal injection of 105 vancomycin- sensitive or -resistant E faecalis organisms in one eye. Infections were allowed to proceed 3 hours before dividing animals randomly into the following treatment groups (n=6, each): the vancomycin-sensitive E faecalis model-(1) vancomycin (1 mg/0.1 mL), (2) combined vancomycin (1 mg/0.1 mL) and amikacin (0.4 mg/0.1 mL), (3) combined vancomycin (1 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), (4) combined vancomycin (1 mg/0.1 mL) and ceftazidime (2 mg/0.1 mL), (5) combined ampicillin (5 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), and (6) pristinamycin (1 mg/0.1 mL); and the vancomycin-resistant E faecalis model-(1) same as above, excluding group 4. Control groups received sterile balanced salt solution. Twenty-four hours following intravitreal treatment, vitreous humor was collected for quantitative bacteriological studies. Results: Intravitreal therapy with combined vancomycin and amikacin provided the most effective reduction of vancomycin-sensitive E faecalis organisms compared with combined vancomycin and gentamicin therapy (P=.10, Wilcoxon's rank sum test) or any other treatment group (P<.01, Wilcoxon's rank sum test). For vancomycin-resistant E faecalis endophthalmitis model, the combined ampicillin and gentamicin therapy was the most effective, followed by the combined vancomycin and amikacin therapy (P<.01, Wilcoxon's rank sum test). Conclusions: Treatment with intravitreal vancomycin plus amikacin and with intravitreal ampicillin plus gentamicin provide an effective bactericidal therapy for severe experimental vancomycin-sensitive and -resistant E faecalis endophthalmitis, respectively.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalArchives of Ophthalmology
Volume114
Issue number1
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Investigational Therapies
Endophthalmitis
Enterococcus faecalis
Vancomycin
Anti-Bacterial Agents
Nonparametric Statistics
Gentamicins
Amikacin
Ampicillin
Therapeutics
Pristinamycin
Vitreous Body
Intravitreal Injections
Ceftazidime

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Comparative intravitreal antibiotic therapy for experimental Enterococcus faecalis endophthalmitis. / Choi, Sangkyung; Hahn, Tae Won; Osterhout, Gerard; O'Brien, Terrence.

In: Archives of Ophthalmology, Vol. 114, No. 1, 01.01.1996, p. 61-65.

Research output: Contribution to journalArticle

Choi, Sangkyung ; Hahn, Tae Won ; Osterhout, Gerard ; O'Brien, Terrence. / Comparative intravitreal antibiotic therapy for experimental Enterococcus faecalis endophthalmitis. In: Archives of Ophthalmology. 1996 ; Vol. 114, No. 1. pp. 61-65.
@article{342491673d724064bebc67030a66d8b8,
title = "Comparative intravitreal antibiotic therapy for experimental Enterococcus faecalis endophthalmitis",
abstract = "Objective: To evaluate the most effective intravitreal antibiotic treatment of vancomycin-sensitive and -resistant Enterococcus faecalis endophthalmitis. Design: Animal experiment. Setting: Seventy-eight New Zealand white rabbits received an intravitreal injection of 105 vancomycin- sensitive or -resistant E faecalis organisms in one eye. Infections were allowed to proceed 3 hours before dividing animals randomly into the following treatment groups (n=6, each): the vancomycin-sensitive E faecalis model-(1) vancomycin (1 mg/0.1 mL), (2) combined vancomycin (1 mg/0.1 mL) and amikacin (0.4 mg/0.1 mL), (3) combined vancomycin (1 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), (4) combined vancomycin (1 mg/0.1 mL) and ceftazidime (2 mg/0.1 mL), (5) combined ampicillin (5 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), and (6) pristinamycin (1 mg/0.1 mL); and the vancomycin-resistant E faecalis model-(1) same as above, excluding group 4. Control groups received sterile balanced salt solution. Twenty-four hours following intravitreal treatment, vitreous humor was collected for quantitative bacteriological studies. Results: Intravitreal therapy with combined vancomycin and amikacin provided the most effective reduction of vancomycin-sensitive E faecalis organisms compared with combined vancomycin and gentamicin therapy (P=.10, Wilcoxon's rank sum test) or any other treatment group (P<.01, Wilcoxon's rank sum test). For vancomycin-resistant E faecalis endophthalmitis model, the combined ampicillin and gentamicin therapy was the most effective, followed by the combined vancomycin and amikacin therapy (P<.01, Wilcoxon's rank sum test). Conclusions: Treatment with intravitreal vancomycin plus amikacin and with intravitreal ampicillin plus gentamicin provide an effective bactericidal therapy for severe experimental vancomycin-sensitive and -resistant E faecalis endophthalmitis, respectively.",
author = "Sangkyung Choi and Hahn, {Tae Won} and Gerard Osterhout and Terrence O'Brien",
year = "1996",
month = "1",
day = "1",
language = "English",
volume = "114",
pages = "61--65",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Comparative intravitreal antibiotic therapy for experimental Enterococcus faecalis endophthalmitis

AU - Choi, Sangkyung

AU - Hahn, Tae Won

AU - Osterhout, Gerard

AU - O'Brien, Terrence

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Objective: To evaluate the most effective intravitreal antibiotic treatment of vancomycin-sensitive and -resistant Enterococcus faecalis endophthalmitis. Design: Animal experiment. Setting: Seventy-eight New Zealand white rabbits received an intravitreal injection of 105 vancomycin- sensitive or -resistant E faecalis organisms in one eye. Infections were allowed to proceed 3 hours before dividing animals randomly into the following treatment groups (n=6, each): the vancomycin-sensitive E faecalis model-(1) vancomycin (1 mg/0.1 mL), (2) combined vancomycin (1 mg/0.1 mL) and amikacin (0.4 mg/0.1 mL), (3) combined vancomycin (1 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), (4) combined vancomycin (1 mg/0.1 mL) and ceftazidime (2 mg/0.1 mL), (5) combined ampicillin (5 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), and (6) pristinamycin (1 mg/0.1 mL); and the vancomycin-resistant E faecalis model-(1) same as above, excluding group 4. Control groups received sterile balanced salt solution. Twenty-four hours following intravitreal treatment, vitreous humor was collected for quantitative bacteriological studies. Results: Intravitreal therapy with combined vancomycin and amikacin provided the most effective reduction of vancomycin-sensitive E faecalis organisms compared with combined vancomycin and gentamicin therapy (P=.10, Wilcoxon's rank sum test) or any other treatment group (P<.01, Wilcoxon's rank sum test). For vancomycin-resistant E faecalis endophthalmitis model, the combined ampicillin and gentamicin therapy was the most effective, followed by the combined vancomycin and amikacin therapy (P<.01, Wilcoxon's rank sum test). Conclusions: Treatment with intravitreal vancomycin plus amikacin and with intravitreal ampicillin plus gentamicin provide an effective bactericidal therapy for severe experimental vancomycin-sensitive and -resistant E faecalis endophthalmitis, respectively.

AB - Objective: To evaluate the most effective intravitreal antibiotic treatment of vancomycin-sensitive and -resistant Enterococcus faecalis endophthalmitis. Design: Animal experiment. Setting: Seventy-eight New Zealand white rabbits received an intravitreal injection of 105 vancomycin- sensitive or -resistant E faecalis organisms in one eye. Infections were allowed to proceed 3 hours before dividing animals randomly into the following treatment groups (n=6, each): the vancomycin-sensitive E faecalis model-(1) vancomycin (1 mg/0.1 mL), (2) combined vancomycin (1 mg/0.1 mL) and amikacin (0.4 mg/0.1 mL), (3) combined vancomycin (1 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), (4) combined vancomycin (1 mg/0.1 mL) and ceftazidime (2 mg/0.1 mL), (5) combined ampicillin (5 mg/0.1 mL) and gentamicin (0.1 mg/0.1 mL), and (6) pristinamycin (1 mg/0.1 mL); and the vancomycin-resistant E faecalis model-(1) same as above, excluding group 4. Control groups received sterile balanced salt solution. Twenty-four hours following intravitreal treatment, vitreous humor was collected for quantitative bacteriological studies. Results: Intravitreal therapy with combined vancomycin and amikacin provided the most effective reduction of vancomycin-sensitive E faecalis organisms compared with combined vancomycin and gentamicin therapy (P=.10, Wilcoxon's rank sum test) or any other treatment group (P<.01, Wilcoxon's rank sum test). For vancomycin-resistant E faecalis endophthalmitis model, the combined ampicillin and gentamicin therapy was the most effective, followed by the combined vancomycin and amikacin therapy (P<.01, Wilcoxon's rank sum test). Conclusions: Treatment with intravitreal vancomycin plus amikacin and with intravitreal ampicillin plus gentamicin provide an effective bactericidal therapy for severe experimental vancomycin-sensitive and -resistant E faecalis endophthalmitis, respectively.

UR - http://www.scopus.com/inward/record.url?scp=9044237690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044237690&partnerID=8YFLogxK

M3 - Article

C2 - 8540852

AN - SCOPUS:9044237690

VL - 114

SP - 61

EP - 65

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 1

ER -